Women with PMOS should get subsidised weight-loss drugs, Australian advocates say
Australian health advocates are urging the government to subsidise GLP‑1 weight‑loss medications for women diagnosed with polycystic ovary syndrome. Although the drugs are not formally approved by the Therapeutic Goods Administration for this condition, doctors are prescribing them off‑label to address obesity and related symptoms. The campaign seeks broader public funding to improve access in Australia.